Can ENDS technology facilitate the delivery of medicines?

Over the past decade Electronic Nicotine Delivery System (ENDS) have established themselves commercially as an alternative to tobacco cigarettes. The use of these devices deliver pharmaceutical active ingredients has also been reported in literature; however, achievement therapeutic dose usually required a large number puffs. Promisingly, were shown generate aerosols within optimal aerodynamic particle size distribution achieve deep lung deposition. Moreover, they demonstrate ability be efficient drug delivery systems for patients with poor function or anatomy, can offer tailored aerosol medicine. This study was conducted aim successfully delivering free base salbutamol via inhalation using e-liquid formulations, aerosolized ENDS technology. E-liquids formulations containing ingredient prepared; impaction data collected Next Generation Impactor under laminar flow conditions and evaluated Copley's Inhaler Testing Data Analysis Software (CITDAS). showed up 245 μg/puff Mass Median Aerodynamic Diameter (MMAD) ranging 1.2–1.4 μm. results this suggest that technology medicine represent innovation, potentially technology, could close existing gap currently available between inhaler design patients’ compliance adherence.